JP2023541928A5 - - Google Patents
Info
- Publication number
- JP2023541928A5 JP2023541928A5 JP2023516800A JP2023516800A JP2023541928A5 JP 2023541928 A5 JP2023541928 A5 JP 2023541928A5 JP 2023516800 A JP2023516800 A JP 2023516800A JP 2023516800 A JP2023516800 A JP 2023516800A JP 2023541928 A5 JP2023541928 A5 JP 2023541928A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- application publication
- release
- patent application
- document
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/028,403 | 2020-09-22 | ||
| US17/028,403 US11684596B2 (en) | 2020-09-22 | 2020-09-22 | Antidiabetic pharmaceutical compositions and preparation method thereof |
| PCT/US2021/048104 WO2022066363A1 (en) | 2020-09-22 | 2021-08-27 | Antidiabetic pharmaceutical compositions and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541928A JP2023541928A (ja) | 2023-10-04 |
| JP2023541928A5 true JP2023541928A5 (https=) | 2024-09-03 |
Family
ID=80739639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516800A Pending JP2023541928A (ja) | 2020-09-22 | 2021-08-27 | 抗糖尿病医薬組成物およびその調製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11684596B2 (https=) |
| EP (1) | EP4216942A4 (https=) |
| JP (1) | JP2023541928A (https=) |
| KR (1) | KR20230093255A (https=) |
| CN (1) | CN114929210A (https=) |
| AU (1) | AU2021349178A1 (https=) |
| BR (1) | BR112023005228A2 (https=) |
| CA (1) | CA3192584A1 (https=) |
| WO (1) | WO2022066363A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20251270A1 (es) * | 2022-08-24 | 2025-05-14 | Dong A St Co Ltd | Formulacion oral compuesta que comprende evogliptina y metformina, y metodos de preparacion de la misma |
| EP4709359A1 (en) * | 2023-05-10 | 2026-03-18 | Elite Pharmaceutical Solution Inc. | Oral dosage forms of metformin and preparation method thereof |
| US20240374542A1 (en) * | 2023-05-10 | 2024-11-14 | Elite Pharmaceutical Solution Inc. | Oral dosage forms of metformin and preparation method thereof |
| WO2025132901A1 (en) | 2023-12-22 | 2025-06-26 | Krka, D.D., Novo Mesto | Bilayer tablet formulation comprising dapagliflozin and metformin |
| KR20250154775A (ko) * | 2024-04-22 | 2025-10-29 | 제이피바이오 주식회사 | 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| AU2003272504A1 (en) * | 2002-09-20 | 2004-04-08 | Andrx Labs Llc | Multistage formulation containing a biguanide and thiazolidindione derivatives |
| MXPA06003453A (es) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Barra de empuje oros para el suministro controlado de agentes activos. |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| US20100323011A1 (en) * | 2008-03-04 | 2010-12-23 | Nazaneen Pourkavoos | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| CN101940578B (zh) * | 2010-08-25 | 2012-07-25 | 山东新华制药股份有限公司 | 一种用于治疗2型糖尿病的药物组合物及其制备方法 |
| CN101984974B (zh) * | 2010-11-15 | 2013-04-17 | 山东新华制药股份有限公司 | 一种用于治疗2型糖尿病的药物组合物的制备方法 |
| CN102727459A (zh) * | 2011-04-15 | 2012-10-17 | 江苏豪森医药集团有限公司 | 一种具有第一和第二活性药物的制剂 |
| US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CN103285398B (zh) * | 2013-06-28 | 2015-07-22 | 青岛黄海制药有限责任公司 | 含有dpp-ⅳ抑制剂和第二种糖尿病药物的复方制剂及其制备方法 |
| CN103933031B (zh) * | 2014-05-13 | 2017-01-18 | 中国药科大学 | 一种含有dpp‑4抑制剂和盐酸二甲双胍的复方制剂及其制备方法 |
| CN105878256B (zh) * | 2015-01-05 | 2019-10-22 | 合肥立方制药股份有限公司 | 含有盐酸二甲双胍和格列美脲的控释制剂及其制备方法 |
| CN104940159B (zh) * | 2015-07-15 | 2018-09-18 | 山东司邦得制药有限公司 | 一种盐酸二甲双胍控释片及其制备方法与应用 |
| US10987311B2 (en) * | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| US20200289420A1 (en) * | 2019-03-17 | 2020-09-17 | Elite Pharmaceutical Solution Inc. | Pharmaceutical compositions for treating diabetes and preparation method thereof |
-
2020
- 2020-09-22 US US17/028,403 patent/US11684596B2/en active Active
-
2021
- 2021-08-27 BR BR112023005228A patent/BR112023005228A2/pt unknown
- 2021-08-27 JP JP2023516800A patent/JP2023541928A/ja active Pending
- 2021-08-27 AU AU2021349178A patent/AU2021349178A1/en not_active Abandoned
- 2021-08-27 KR KR1020237012942A patent/KR20230093255A/ko active Pending
- 2021-08-27 WO PCT/US2021/048104 patent/WO2022066363A1/en not_active Ceased
- 2021-08-27 CN CN202180007373.XA patent/CN114929210A/zh active Pending
- 2021-08-27 CA CA3192584A patent/CA3192584A1/en active Pending
- 2021-08-27 EP EP21873168.5A patent/EP4216942A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541928A5 (https=) | ||
| JP2008523153A5 (https=) | ||
| JP2021524958A5 (https=) | ||
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| JP2019513799A5 (https=) | ||
| JP2005518433A5 (https=) | ||
| JP2025161856A5 (https=) | ||
| WO2002002638A3 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| WO2005105141A3 (en) | Combined meningococcal conjugates with common carrier protein | |
| JP2023166406A5 (https=) | ||
| JP2005531614A5 (https=) | ||
| JP2007520566A5 (https=) | ||
| JP2021529829A5 (https=) | ||
| JP2009538898A5 (https=) | ||
| CR9363A (es) | Composiciones para la transmision transmucosa oral de la metformina | |
| JP2014521641A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| JP2020536098A5 (https=) | ||
| JP2023549849A5 (https=) | ||
| PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
| JP2025509278A5 (https=) | ||
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| JP2023521031A5 (https=) | ||
| RU2006127422A (ru) | Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм |